Mgc Pharmaceuticals Share Discussion Threads

[goforgold1] 30/1/2023 07:23

$2.86m for administration costs. Ha ha wow unbelievable. Easy money when you can scam it.

[heatseek77] 25/1/2023 08:27

Come on you ugly 🥚 nonce buy some cpi, alot better on that thread since you stopped trolling it 🥱🥱🥱🥱

[heatseek77] 25/1/2023 08:24

1m to sell you don't own anything nevermind a million

[heatseek77] 25/1/2023 08:23

yourafatmanV88 you really are a sad lonely 🥚 troll gal, you and your best mate Murphy 🥚
You must have been gutted when they stopped you posting as bad robot so sad get a life, always talks sh1te always wrong fatmanv88

[ibatman ver2] 24/1/2023 12:24

Selling below 0.50, price 0.489p for 1m.

Mercer is dumping shares here and will convert at 0.4p. Then next month, 0.25p conversion price.

[heatseek77] 22/1/2023 09:40

Heisafatmanv88 amazing you've been posting as one of your many sado aliases the same rubbish for a year and half now..... Get a life you lonely sad 🥚 head

[heatseek77] 19/1/2023 07:00

See some heisaFatmanv88 egg still conversing with himself - so so sad 😭
Did you buy any capita Fatman nancy?

[heatseek77] 18/1/2023 14:26

Goldilocks spikey spikey, you've been shouting the same sh1te for the last 2 yrs yawn yawn - suppose the cabbie business in dirty Manc is just dogs

[ibatman ver2] 17/1/2023 13:52

Another cln is coming by the following Friday, as it's payday. Hence the big block sells.

Most probably, they will get 0.4p next conversion.

[sloppyjoe2] 16/1/2023 08:29

"Their experience and understanding of the Company will further enhance our ability to maximise enterprise value for our shareholders going forward." Has that clown looked at the share price lately?

[looneytune] 16/1/2023 07:16

16/01/2023 7:00am
RNS Non-Regulatory

TIDMMXC

MGC Pharmaceuticals Limited

16 January 2023

MGC Pharmaceuticals Ltd.

Change of Adviser - SW4 Partners

16 January 2023

ASX, LSE: MXC

MGC Pharmaceuticals Ltd (' MGC Pharma' or ' the Company ') a European based pharmaceutical company specialising in the production and development of plant inspired medicines is pleased to confirm the appointment of SW4 Partners ('SW4'), headed by Rupert Fane and Nilesh Patel as key corporate advisors. SW4 replaces Hannam and Partners as the Company's advisor owing to the Hannam and Partners life science team moving into SW4 Partners.

The SW4 team are highly regarded in the UK advisory space with a long track record in UK capital markets, mergers and acquisitions, as well as corporate finance structuring in the UK and EU life science sector.

Roby Zomer, co-founder, Managing Director and CEO of MGC Pharmaceuticals, commented : " We are pleased to be continuing our successful partnership with the team now at SW4. Their experience and understanding of the Company will further enhance our ability to maximise enterprise value for our shareholders going forward."

--Ends--

Authorised for release by the Company Secretary, for further information please contact:

[gotterdammerung] 10/1/2023 09:35

Good positive news today. Certainly on right track now. Think a strong recovery in share will follow.

[looneytune] 09/1/2023 22:00

News incoming:-


January 2023 ASX Code: MXC LSE Code: MXC
Completion of CimetrATM bioanalytics Pre-clinical Trial
Key Highlights:
• •
• • • •
•
MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has completed the pre-clinical rodent studies on CimetrATM, which are a key step in the clinical pathway prior to the planned FDA Investigational New Drug submission. Research using rodent and mammalian models are used to delineate the pharmacokinetic profile and general safety of a drug, as well as to identify toxicity patterns over a given period for the treatment before it advances to the next stage of trials, as required by US Food and Drug Administration (FDA) criteria.
The Study was undertaken to determine toxicological effects of CimetrATM over a 14-day period in rats, and was undertaken by the Smart Assays and Science in Action Laboratories in Israel, and comprised four study groups, three separate dosage groups, and one control group, with the treatment administered over a period of fourteen days, followed by a seven day review period. Blood samples for the pharmacokinetic analysis were taken on a daily basis, and histopathology tests were conducted on all organs per FDA guidelines. No anomalies were observed in the biopsies taken, nor were any clinical or behavioural adverse events recorded.
This Study is crucially important in the regulatory approval process for Investigational New Drugs (IND) approval by the FDA, and forms a key part of the metrics for the FDA's Center for Drug Evaluation and Research (CDER), the commercial and consumer watchdog, and gatekeeper to the US pharmaceutical market. There is a strict process for FDA approval: discovery, preclinical development, and clinical trial, where the boundary between preclinical development and clinical trial is sharply defined by the IND approval. Final FDA approvals will ensure that CimetrATM meets the criteria for further clinical study and
1 - 7
MGC Pharma has completed the full pre-clinical rodents study panel for CimetrATM.
The latest study, which was carried out at the Smart Assays laboratory in Israel,
included the development of bioanalytical methods and validations for further
pharmacokinetic analysis for CimetrATM.
A study on chronic toxicity in rodents was also completed by Science in Action, in Israel,
monitoring the potential development of adverse effects from using CimetrATM.
Histopathology demonstrated the full safety profile for CimetrATM across all study
dosage groups.
The study results are an important step ahead of the submission to the US Food and
Drug Administration (FDA) for Investigational New Drug (IND) approval.
No anomalies were observed in the biopsies, nor were any clinical or behavioural
adverse events recorded.
CimetrATM is MGC Pharma’s proprietary Investigational Medicinal Product which in
previous clinical trials has demonstrated anti-inflammatory and immunomodulating
properties, and is MGC’s most clinically advanced product.

development in the US, and ultimately commercial sale, therefore opening up the largest healthcare market globally to MGC Pharma.
Roby Zomer, co-founder, Managing Director and CEO of MGC Pharmaceuticals, commented: “The successful completion of this study and the excellent results attained is an important milestone moment for the Company, as we continue to progress CimetrATM along the mandated clinical pathway. The results of this study are a critical step in advancing MGC’s submission to the FDA, and for the final approval of CimetrATM as an Investigational New Drug in the US.”
A summary of results from the recently completed study can be found in Annexure A below.
About CimetrATM
CimetrATM is a nanoparticle micellar formulation based on the pharmaceutical synergetic composition consisting of Curcumin and Boswellia. In pre-clinical and clinical trials CimetrATM has demonstrated anti- inflammatory and immunomodulating effects, and can be designed for multiple therapeutic applications utilising Graft Polymer IP Ltd’s proprietary GraftBioTM Self-nano-emulsifying Drug Delivery System.
Preclinical and clinical results to date have demonstrated CimetrATM's mechanism of action as an anti- inflammatory and immunomodulatory agent which is effective in the prevention of severe inflammation by its control of increased Cytokine production resulting from an infection of the different variants of SARS-CoV-2 (the virus responsible for COVID-19); and which is the forerunner of a Cytokine Storm, which is believed to be the main reason for mortality in severe COVID-19 patients.
Authorised for release by the Board, for further information please contact:
MGC Pharmaceuticals Ltd
Roby Zomer
CEO & Managing Director [phone] [e-mail]
UK Financial and Corporate Advisor
Hannam & Partners
Rupert Fane / Nilesh Patel
[phone]
[e-mail] / [e-mail]
UK PR Advisors
Tavistock
Charles Vivian / Tim Pearson [phone] [e-mail]
About MGC Pharma
MGC Pharmaceuticals Ltd
David Lim
Company Secretary
[phone] [e-mail]
UK Broker
Turner Pope
Andy Thacker
[phone] [e-mail]
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on develo

[gotterdammerung] 04/1/2023 15:44

Agree undervalued. Great time to add to
Holdings.